Pacira BioSciences' Net Income towards Common Stockholders rose 10378.63% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.4 million, marking a year-over-year increase of 12362.81%. This contributed to the annual value of -$99.6 million for FY2024, which is 33730.19% down from last year.
Latest data reveals that Pacira BioSciences reported Net Income towards Common Stockholders of $5.4 million as of Q3 2025, which was up 10378.63% from -$4.8 million recorded in Q2 2025.
Pacira BioSciences' Net Income towards Common Stockholders' 5-year high stood at $25.8 million during Q2 2023, with a 5-year trough of -$143.5 million in Q3 2024.
For the 5-year period, Pacira BioSciences' Net Income towards Common Stockholders averaged around $296631.6, with its median value being $9.0 million (2024).
In the last 5 years, Pacira BioSciences' Net Income towards Common Stockholders surged by 166681.1% in 2023 and then plummeted by 142129.31% in 2024.
Quarter analysis of 5 years shows Pacira BioSciences' Net Income towards Common Stockholders stood at -$5.1 million in 2021, then tumbled by 96.92% to -$10.1 million in 2022, then skyrocketed by 346.19% to $24.9 million in 2023, then crashed by 35.5% to $16.0 million in 2024, then plummeted by 66.14% to $5.4 million in 2025.
Its last three reported values are $5.4 million in Q3 2025, -$4.8 million for Q2 2025, and $4.8 million during Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value